Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EIS-12656 |
Synonyms | |
Therapy Description |
Limited information is currently available on EIS-12656, a putative small molecule inhibitor of ALC1 (Jul 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EIS-12656 | EIS12656|EIS 12656 | Limited information is currently available on EIS-12656, a putative small molecule inhibitor of ALC1 (Jul 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06525298 | Phase Ib/II | EIS-12656 EIS-12656 + Olaparib EIS-12656 + Trastuzumab deruxtecan | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | Recruiting | USA | 0 |